Get started

EDIT

EDIT Editas medicine ready to break outBeen in this for a little while now since the change in market structure and added a few times to this position so not the best avg weighted entry but still well in profit. Classic sweep of lows and change in market structure has me excited on this position and more recently over the last month with the gap up above the previous short term high and now the ascending triangle forming showing the bulls still buying up and testing that resistance. The resistance may be strong but we have had a few cracks at it already and eventually I expect this level to break and to see another descent impulse move. Bullish on EDIT for now, momentum still on our side.
NASDAQ:EDITLong
by DeNomics
1
EDIT - another genomics name that looks ready All major gene editing stocks look like they're on the cusp of big moves higher. (See last post on NTLA) Zoomed in on the shorter time frame we have a trigger off the 618 4hr retrace. There's some overhead supply in the 50s for shorter term targets, but this is a long term play with much higher upside. Seeing similar in CRSP, but EDIT is showing a more significant breakout on the monthly time frame Short term quick look at CRSP: NTLA is the leader in the sector right now, but that could change fast. I am long all three
NASDAQ:EDITLong
by Lanmar
EDIT Genome Editing Long-Term SwingEDIT NASDAQ:EDIT is a genome editing company with treatments being developed for Leber congenital amaurosis**, Usher syndrome, neurological diseases, Sickle cell disease, beta-thalassemia, as well as cancer treatments through NK cells. The leber congenital amaurosis clinical trial is currently the furthest along but still in its earlier stages but has completed dosing all of its patients. The results of that clinical trial will be HUGE. That will set the blueprint for EDIT as a company. The same principles for that EDIT-101 clinical trial are being applied to multiple other medicines and can lay the blueprint for huge medical breakthroughs. ARK believes genome editing is the future of medicine and I agree. This 46% sell off since EDIT’s highs looks to be a strong bounce area. I grabbed a small starter position on Friday last week but will look to add to my position this week and add dips to $50. If we fail $50.48 HVN area I will use that as my stop. Chart: EDIT looks to be in a prime bounce zone right now and I will be looking for it to hold the HVN area ($57-$66) for some consolidation. Daily .618 fib retracement line has served as support multiple times and will want that to hold up this week. Need some volume to being accumulating on EDIT and close back over the $58 lvl.
NASDAQ:EDITLong
by DOpeTrades
1
EDIT 3 day chart bullish signalI started covering CRSP/NTLA/EDIT way back last year in August while they haven't caught people's attention staying under the radar. Now they have made significant move but the move will continue it seems. EDIT 3 day chart shows hidden divergence of StocRSI while price staying above key MAs. On the near term EDIT might see some selling pressure it looks like with the day chart bearish Pin bar. watch out for some good buying opportunities. Holding positions. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
NASDAQ:EDIT
by hanzhao311
EDIT - EDITAS Genetics time to accumulate and play bounceHello all, Notice MACD, RSI and 50 day MA trends for EDIT. I am planning to accumulate calls this week and some last week to play the bounce signaled by RSI and MACD into the JPM healthcare conference on the 15th where these biotechs present promising results and play pop. Plus biotech is a risky defensive bet - mutually exclusive of Iran - these biotechs are still getting bought out and FDA is approving new drugs like candy.
NASDAQ:EDITLong
by ketokat